POSTER 66

Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23–Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-Blind, Placebo-Controlled ICONIC-LEAD Trial

Robert Bissonnette, Jennifer Soung, Adelaide Hebert, Andrew E. Pink, Andreas Pinter, Yuling Shi, Megan Miller, Joseph Cafone, Jing Zhi (Gigi) Jiang, Cynthia DeKlotz, Mark G. Lebwohl

< Previous Poster | Next Poster >

Poster 66